Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?

Shares of Hims & Hers Health (NYSE: HIMS) skyrocketed after the telemedicine platform came to an agreement with Novo Nordisk (NYSE: NVO) to sell the drugmaker's popular GLP-1 weight loss drugs. The question on many investors' minds is whether it is too late to buy the stock. Let's take a closer look.  Hims & Hers and Novo Nordisk have had a tumultuous relationship over the past couple of years. The companies formed a short-lived commercial partnership last year, only for Novo Nordisk to walk away, saying that Hims had not lived up to its end of the bargain by continuing to illegally sell compounded versions of its drugs under the guise of personalization. Hims had legally been able to sell the compounded drugs when semaglutide, the main ingredient in Novo's Wegovy and Ozempic drugs, was in shortage. However, the FDA declared the drug was no longer in shortage in February 2025. Hims had long contended that it had the legal right to sell personalized versions of these drugs and that it was best for patients. At the time of the breakup, the company said that Novo Nordisk was pressuring it to sell the branded version of its drugs and that it would not be "strong-armed." Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool